BioMarin Pharmaceutical Inc., a leading global biotechnology entity, unveiled that its drug, VOXZOGO (vosoritide), has received the green light from the U.S. Food and Drug Administration (FDA) to enhance linear growth in pediatric patients of all ages with open epiphyses (growth plates) suffering from achondroplasia. Key Highlights from the Approval Previously, the drug’s indication was […]
BioMarin Pharmaceutical has signed a preclinical collaboration and license deal with Swiss gene therapy platform company DiNAQOR to develop novel gene therapies for the treatment of rare genetic cardiomyopathies. DiNAQOR will get an undisclosed upfront payment and will stand to receive development, regulatory and commercial milestones on product sales apart from tiered royalties on global […]
